Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ensatinib
DRUG
2 trials
Sponsors
Peking University Cancer Hospital & Institute
, Sichuan University
Conditions
ALK Fusion Protein Expression
ALK Positive
Adjuvant Therapy
NSCLC Stage IIIB
NSCLC Stage IV
Non-Small Cell Lung Cancer
Phase 2
A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
Not yet recruiting
NCT05186506
Sichuan University
Adjuvant Therapy, ALK Fusion Protein Expression, Non-Small Cell Lung Cancer
Start: 2022-01-01
End: 2028-12-20
Target: 152
Updated: 2022-01-11
Unknown Phase
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
NCT05132218
Peking University Cancer Hospital & Institute
ALK Positive, NSCLC Stage IIIB, NSCLC Stage IV
Start: 2021-10-19
End: 2024-10-30
Target: 180
Updated: 2021-11-24